Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza.

Scott, Claire; Kankanala, Jayakanth; Foster, Toshana L; Goldhill, Daniel H; Bao, Peng; Simmons, Katie; Pingen, Marieke; Bentham, Matthew; Atkins, Elizabeth; Loundras, Eleni; +13 more... Elderfield, Ruth; Claridge, Jolyon K; Thompson, Joseph; Stilwell, Peter R; Tathineni, Ranjitha; McKimmie, Clive S; Targett-Adams, Paul; Schnell, Jason R; Cook, Graham P; Evans, Stephen; Barclay, Wendy S; Foster, Richard; Griffin, Stephen; (2020) Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza. PLOS PATHOGENS, 16 (8). e1008716. ISSN 1553-7366 DOI: https://doi.org/10.1371/journal.ppat.1008716

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1371/journal.ppat.1008716

Abstract

Share

Download

Filename: Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influen.pdf

Licence: Creative Commons: Attribution 3.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar